Cargando…

KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma

KRAS mutations define a clinically-distinct subgroup of lung adenocarcinoma patients, characterized by smoking history, resistance to EGFR-targeted therapies, and adverse prognosis. Whether KRAS- mutated lung adenocarcinomas also have distinct histopathologic features is not well established. We tes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rekhtman, Natasha, Ang, Daphne C., Riely, Gregory J., Ladanyi, Marc, Moreira, Andre L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3732528/ https://www.ncbi.nlm.nih.gov/pubmed/23619604 http://dx.doi.org/10.1038/modpathol.2013.74

Ejemplares similares

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers
por: Drilon, Alexander, et al.
Publicado: (2019)

Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations
por: Arbour, Kathryn C., et al.
Publicado: (2021)

The Impact of Cigarette Smoking on the Frequency of and Qualitative Differences in KRAS Mutations in Korean Patients with Lung Adenocarcinoma
por: Kim, Hye Ryun, et al.
Publicado: (2013)

SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor Inhibitors
por: Sato, Hiroki, et al.
Publicado: (2022)

Evaluation of KRAS Concomitant Mutations in Advanced Lung Adenocarcinoma Patients
por: Aran, Veronica, et al.
Publicado: (2021)

KRAS and EGFR mutations coexisting in lung adenocarcinoma
por: Sousa, Vitor, et al.
Publicado: (2010)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large cell carcinoma
por: Rekhtman, Natasha, et al.
Publicado: (2012)

KRAS-Driven Lung Adenocarcinoma and B Cell Infiltration: Novel Insights for Immunotherapy
por: Rosamaria, Pinto, et al.
Publicado: (2019)

Enumeration of leukocyte infiltration in solid tumors by confocal laser scanning microscopy
por: Biggerstaff, J, et al.
Publicado: (2006)

Somatic mutations in leukocytes infiltrating primary breast cancers
por: Kleppe, Maria, et al.
Publicado: (2015)

Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation
por: Zeng, Da-xiong, et al.
Publicado: (2017)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: Napsin A expression and genomic alterations
por: Rekhtman, Natasha, et al.
Publicado: (2017)

Characterization of Infiltrating Immune Cells and Secretory or Membrane-Associated Proteins in KRAS Lung Adenocarcinoma
por: Bian, Yunyi, et al.
Publicado: (2023)

A Phase 2 Single Arm Trial of Cabozantinib in Patients with Advanced RET-Rearranged Lung Cancers
por: Drilon, Alexander, et al.
Publicado: (2016)

Tumor-Infiltrating Leukocyte Phenotypes Distinguish Outcomes in Related Patients With Pancreatic Adenocarcinoma
por: Link, Jason M., et al.
Publicado: (2021)

Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma
por: Stefanius, Karoliina, et al.
Publicado: (2011)

KRAS mutational concordance between primary and metastatic colorectal adenocarcinoma
por: PALIOGIANNIS, PANAGIOTIS, et al.
Publicado: (2014)

Frequency and Spectrum of KRAS Mutations in Moroccan Patients with Lung Adenocarcinoma
por: Elghissassi, Ibrahim, et al.
Publicado: (2014)

Metachronous primary lung adenocarcinomas harboring distinct KRAS mutations
por: Hu, Yan, et al.
Publicado: (2020)

Highlights on the Role of KRAS Mutations in Reshaping the Microenvironment of Pancreatic Adenocarcinoma
por: Hafezi, Shirin, et al.
Publicado: (2021)

Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma
por: Liu, Yu-Huei, et al.
Publicado: (2022)

KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression
por: Zhang, Zining, et al.
Publicado: (2023)

Impact of KRAS Mutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal Adenocarcinoma
por: Yousef, Abdelrahman, et al.
Publicado: (2023)

KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas
por: Gu, Meichen, et al.
Publicado: (2021)

Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors
por: Arbour, Kathryn C., et al.
Publicado: (2017)

Advances in Fine Needle Aspiration Cytology for the Diagnosis of Pulmonary Carcinoma
por: Hasanovic, Adnan, et al.
Publicado: (2011)

KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas
por: Gu, Meichen, et al.
Publicado: (2021)

KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis
por: Lohinai, Zoltan, et al.
Publicado: (2017)

Clinical-Pathological Correlation of KRAS Mutation Status in Metastatic Colorectal Adenocarcinoma
por: Ribeiro, Karen Bento, et al.
Publicado: (2013)

EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2019)

Leukocyte infiltration in experimental stroke
por: Grønberg, Nina Vindegaard, et al.
Publicado: (2013)

Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non–Small Cell Lung Cancer
por: Thummalapalli, Rohit, et al.
Publicado: (2023)

SMARCA4 mutations in KRAS‐mutant lung adenocarcinoma: a multi‐cohort analysis
por: Liu, Liang, et al.
Publicado: (2020)

KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma
por: Bournet, Barbara, et al.
Publicado: (2016)

Regulation and Therapeutic Targeting of MTHFD2 and EZH2 in KRAS-Mutated Human Pulmonary Adenocarcinoma
por: Li, Yuchan, et al.
Publicado: (2022)

EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma
por: Szablewski, Vanessa, et al.
Publicado: (2013)

Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to EGFR and KRAS Mutation Status
por: Planck, Maria, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_arj9jpv3j08rn0e2b6b3vtf04q